The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Sam Engel, MD: Ertugliflozin Two-Year Impact on Renal Function
Investigators presented results of a study that analyzed renal function and markers of kidney damage in more than 1,000 patients in two randomized trials examining ertugliflozin.
Ofri Mosenzon, MD: Dapagliflozin Impact on Renal Outcomes
A study analyzing the renal outcomes of the DECLARE-TIMI 58 trial were presented at ADA 2019 in San Francisco, CA.
Cardiovascular Risks Inflict Nearly Half of All Type 1 Diabetes Patients
A new study shows patients with T1D and comorbid cardiovascular disease face a signficantly greater cost of care.
Chris Sorli, MD: Renal Function on Toujeo versus Tresiba
A recent analysis of the BRIGHT trial examining renal function of insulin glargine 300u/mL versus insulin degludec 100u/mL was presented at ADA 2019.
Patrick Burgess, MD: Biggest Challenges Facing Diabetes Patients
After making the rounds at ADA 2019, Patrick Burgess, MD, discusses what he thinks is the most important discussion taking place at this year's conference and the biggest challenge facing diabetes patients.
Joanna Khatib, MD: Insulin Use Raises Risk of Severe Cardiovascular Events
An analysis of 7 trials examining cardiovascular outcomes of study drugs found that concomitant insulin use increased a patient’s risk of severe cardiovascular outcomes.
Mahmood Kazemi, MD: Effectiveness of FreeStyle Libre for HbA1c Reduction
A meta-analysis of 3 real-world studies into the effectiveness of Abbot's FreeStyle Libre Flash Glucose Monitoring System at ADA 2019.
Sanjoy Paul, PhD: Depression, Antidepressant Use Among Diabetes Patients
A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.
Nicole Handlow: Impact of Multidisciplinary Team on Glycemic Control
Investigators from Allegheny Health Network examined the impact of a multidisciplinary team approach on glycemic control in patients with diabetes in a primary care setting.
Lindsay Clegg, PhD: Effects of SGLT2i with Exenatide on CV, Renal Outcomes
An analysis of results from the EXSCEL trial has suggested that exenatide with SGLT2 inhibitors may reduce major cardiovascular events and improve renal health.
Teplizumab Halves Type 1 Diabetes Diagnoses in Phase 2 Trial
A new study from ADA showed the investigative monoclonal antibody suppressed development and diagnosis of T1D in at-risk patients.
Basal Insulin Has One-Year Window of Benefit Toward Glycemic Control
A new retrospective cohort analysis found that patients with type 2 diabetes generally have about 12 months following BI initiation to achieve A1c < 7.0%.
Trial Compares CV Outcomes in SGLT-2 Inhibitors Versus GLP-1 Agonists
Type 2 diabetes patient outcomes including heart failure, stroke, and myocardial infarction were weighed between the 2 popular drug classes.
New FIELD Study Assessment Links HDL Fractions to T2D Cardiovascular Risks
A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.
Patrick Burgess, MD: Hypoglycemia and Impact of Late Glucose Checks
A study into the impact of the timing of glucose blood readings has found that being 15 to 25 minutes late can almost double a patient's risk of hypoglycemia.
Robert Busch, MD: Icosapent Ethyl for Diabetes Patients, REDUCE-IT Impact
A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.
Sue Kirkman, MD: Hurdles to Overcome in Diabetes Care
UNC professor of medicine discusses her thoughts on the largest challenges for physicians to overcome in the future of diabetes treatment.
Early Initiation of GLP-1RA/SGLT2 Lowers CV Risk, Increase HbA1C Control
Early initiation of GLP-1RA and SGLT2 in patients with T2D resulted in higher odds for long term HbA1C control and for lower CV risk factors.
Five-Year REWIND Results Show Sustained Dulaglutide CV Benefits
The longest clinical assessment of a GLP-1 receptor agonist for cardiovascular outcomes showed a 12% decrease in MACE versus placebo.
Cardiovascular Event Risks Similar in Type 1 & 2 Diabetes Patients
An age-stratified analysis of Swedish national registry data found that myocardial infarction and heart failure rates may even be more prevalent in patients with T1D.
Identifying Type 1 and Type 2 Diabetes Through EHR/EMRs
Sue Kirkman, MD, professor of medicine at UNC Chapel Hill, discusses the results of a study she led that attempted to create a method of identifying what type of diabetes through EHR data.
John Buse, MD: PIONEER 7 Trial of Oral Semaglutide
John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.
The Evolution of Cardiovascular Care after EMPA-REG
It's been 5 years since the FDA approved empagliflozin, and 4 since the major outcomes findings. What is its role in diabetes care today?
PREVIEW Data Shows 96% Diabetes Prevention with Diet, Exercise Management
The three-year trial reported that initial weight loss plus 1 of any 4 diet and exercise programs is associated with major benefits for at-risk patients.
Icosapent Sets New Standard for Macrovascular Disease Prevention
A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.
Oral Semaglutide Compared to Liraglutide
Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.
Developing Oral Semaglutide for Treatment of T2D
Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.
Oral Semaglutide Compared to Empagliflozin for T2D
Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.
ACP Guideline for A1c Levels Provide Cost-Effectiveness for Diabetics
New findings show the controversial 2018 blood sugar control recommendations are associated with cost benefits for 3 subgroups of affected T2D patients.
Vitamin D Supplements Do Not Significantly Reduce Diabetes Risk
A new study which considered the suggested association between type 2 diabetes and vitamin D deficiency did not show a statistically significant reduction of patient risk.